American Society of Hematology

ASH, the world's largest professional society concerned with the causes and treatments of blood disorders, regularly issues press releases highlighting clinical and research advances announced at the ASH annual meeting and published in Blood, as well as releases and statements on breaking policy news affecting the field of hematology.

Need to speak with an expert? Complete our Request An Expert form.

To be added to ASH's press release distribution list, contact Alicia Davids at

Latest Press Releases

  • Statement from ASH President David A. Williams, MD, on Passage of Senate Bill to Repeal Sustainable Growth Rate Apr 15, 2015

    Last night the Senate passed legislation permanently repealing the Sustainable Growth Rate, a flawed formula mandating annual reductions in Medicare physician payments, and replacing it with a 0.5 percent annual physician pay increase for the next five years.

  • American Society of Hematology Provides ‘Bridge Funding’ for Critical Blood Disease Research Apr 14, 2015

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the latest recipients of the ASH Bridge Grant Awards. These one-year, $150,000 awards are designed to provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH due to severe funding reductions. The 11 ASH Bridge Grant recipients announced today join 51 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in 2012.

  • Study: Gene Therapy Superior to Half-Matched Transplant for Children with “Bubble Boy Disease” Apr 13, 2015

    New research published online today in Blood, the Journal of the American Society of Hematology, reports that children with “bubble boy disease” who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder – also known as X-linked severe combined immunodeficiency (SCID-X1) – receiving the two therapeutic approaches.

View all